drugset
drugset / Trial / NCT00515086

Study of Everolimus (RAD001) in Patients With Recurrent Glioblastoma Multiforme (GBM)

NCT00515086 ↗

Phase 2 Terminated 41 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupOpen-labelTreatment

Summary

This study will define the safety and efficacy of Everolimus (RAD001) administered daily in patients with glioblastoma multiforme (GBM)

Timeline

Start
2007-08
Primary completion
2009-08
Completion
2009-08

Outcome

Outcome not reported

Stopped (Enrollment): “Early termination due to slow enrollment and protocol-defined stopping rule.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Everolimus Small molecule 10 mg Oral

Indications

glioblastoma